Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: RXRX.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Recursion Pharmaceuticals (RXRX) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

NEUTRAL

$3.92

+2.3%

2031

5-Year

NEUTRAL

$4.85

+26.7%

Published batch insight

Clinical Validation Battles Dilution Overhang In Platform Biotech Operational Transformation

The reports reflect high consensus that lead candidate clinical progress and pharmaceutical milestone inflows provide crucial fundamental backing, but sharp divergence remains on whether persistent cash burn and inevitable equity dilution will constrain per-share equity appreciation over the five-year forecast horizon.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Sherlock Holmes (Whistleblower), Universal Investor (Polymath), Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Recursion Pharmaceuticals at the forecast anchor (2026-09-18): $12,668 in five years versus $13,892 for S&P 500 benchmark.

Recursion Pharmaceuticals · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Recursion Pharmaceuticals compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 3.83 USD1-year price return: +2.33%5-year price return: +26.68%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	4.05	+5.79%	+5.79%	Presentation of mature Phase 2 TUPELO data for REC-4881 confirms durable polyp reduction. Clinical validation and short covering spark an initial relief rally, partially tempered by restrictive macroeconomic interest rates and year-end positioning.
Q1 2027	3.98	-1.75%	+3.94%	Full-year financial reporting highlights structural cash burn alongside reduced collaboration recognition. Guidance quantifies 2027 clinical spending, prompting investors to refocus on the finite operational runway and trimming post-catalyst speculative sentiment.
Q2 2027	4.10	+3.07%	+7.13%	Initial Phase 1 safety data for REC-7735 and an early discovery option exercise by Genentech provide non-dilutive milestone inflows. Pipeline breadth modestly reassures markets, stabilizing the share price against ongoing sector discount-rate friction.
Q3 2027	3.92	-4.48%	+2.33%	Cash reserves approach critical thresholds, reviving market focus on the early-2028 runway boundary. Heightened anticipation of an equity offering in a high-rate environment introduces mechanical selling pressure, depressing speculative platform multiples.
Q4 2027	3.81	-2.84%	-0.57%	Management executes an underwritten follow-on offering and utilizes at-the-market facilities to secure clinical runway into 2030. Immediate per-share dilution triggers a sharp repricing, resetting the stock price to absorb newly issued common equity.
Q1 2028	3.65	-4.10%	-4.65%	Removal of near-term insolvency risk allows institutional investors to re-engage with reset per-share valuations. REC-4881 advances into registrational cohorts, fostering a modest post-financing stabilization as operational focus shifts to clinical execution.
Q2 2028	3.82	+4.59%	-0.27%	Sanofi advances an immunology target, triggering a contractual milestone payment. The non-dilutive injection validates platform utility, supporting quarterly operating cash flow and lifting sentiment across collaborative pipeline programs.
Q3 2028	3.82	-0.08%	-0.35%	Routine biological attrition in an exploratory oncology cohort reminds market participants of base-rate clinical development hurdles. Pruning an early program narrows pipeline optionality, prompting mild valuation consolidation during late-summer trading.
Q4 2028	3.97	+3.94%	+3.58%	Interim registrational trial monitoring for REC-4881 indicates sustained safety and tolerability in familial adenomatous polyposis. Reduced regulatory ambiguity supports a moderate valuation recovery as long-duration healthcare specialist funds accumulate positions.
Q1 2029	3.96	-0.28%	+3.29%	Annual financial reporting illustrates that expanding multi-site pivotal trial commitments offset earlier post-merger integration efficiencies. Persistent operating cash outflows limit upward multiple expansion, maintaining a tight trading range across pre-commercial biotechs.
Q2 2029	4.07	+2.98%	+6.37%	Roche exercises an option on an advanced collaborative discovery target, delivering non-dilutive cash and external validation. The milestone eases intermediate financing requirements, driving selective institutional buying across collaborative drug discovery platforms.
Q3 2029	4.08	+0.10%	+6.48%	Escalating preparation expenses for registration filings and pre-commercial supply chains expand quarterly operating expenditures. Investors trim speculative positions ahead of pivotal data releases, weighing capital intensity against uncommercialized orphan drug economics.
Q4 2029	4.21	+3.15%	+9.83%	Completed patient enrollment in the REC-4881 registrational study establishes a firm calendar toward primary endpoint readouts. Anticipation of late-stage data generates speculative accumulation, lifting the stock toward multi-quarter highs.
Q1 2030	4.17	-0.85%	+8.89%	Quiet clinical calendars and broader macroeconomic scrutiny over unprofitable technology platforms induce defensive portfolio hedging. The equity consolidates gains while investors await formal independent data monitoring committee evaluations.
Q2 2030	4.43	+6.33%	+15.78%	Topline pivotal data for REC-4881 meets primary endoscopic endpoints, confirming statistically significant polyp reduction. Definitive late-stage clinical validation triggers aggressive short covering and elevates pipeline net asset value benchmarks.
Q3 2030	4.44	+0.24%	+16.06%	Post-catalyst euphoria moderates as sell-side analysts evaluate commercial launch costs and specialized field-force requirements in orphan oncology. Tactical profit-taking ensues while management prepares regulatory filing dossiers.
Q4 2030	4.59	+3.34%	+19.93%	Submission of the New Drug Application for REC-4881 under FDA Priority Review solidifies commercial transition timing. Institutional capital inflows re-rate the enterprise from an experimental platform to an emerging commercial biopharma producer.
Q1 2031	4.66	+1.52%	+21.76%	Commercial inventory buildout and pre-launch marketing outlays expand operating expenses, temporarily masking margin improvements. The equity trades range-bound as investors monitor European regulatory filing acceptance and pricing discussions.
Q2 2031	4.79	+2.82%	+25.19%	FDA approval of REC-4881 grants seven-year orphan drug market exclusivity, validating the core clinical thesis. The milestone drives substantial upward repricing, though gains remain bounded by historical share-count expansion.
Q3 2031	4.85	+1.19%	+26.68%	First commercial product sales and ongoing partner milestone receipts converge toward operational cash-flow breakeven. Market valuation stabilizes around verified commercial orphan economics, concluding the five-year cycle with disciplined per-share compounding.

The central economic thesis hinges on a structural race between clinical de-risking and per-share dilution. Disciplined post-merger rationalization under Dr. Najat Khan has successfully lowered annual cash operating expenses below $375 million, while ongoing Phase 2 trials for lead candidate REC-4881 in familial adenomatous polyposis offer a tangible path toward commercialization. However, with trailing twelve-month free cash burn exceeding $350 million against liquid balances of $557 million, the existing runway terminates in early 2028. Consequently, enterprise value appreciation will be heavily taxed by repeated equity issuance before therapeutic revenues materialize. Valuation sensitivity remains acutely exposed to high macroeconomic discount rates and clinical attrition base rates. The strongest counterargument stresses that computational algorithms cannot bypass systemic human pharmacology, risking catastrophic trial failure.

Key insights

In-licensing provenance of lead clinical assets demonstrates that platform optionality reflects pharmacological translation rather than unassisted de novo algorithmic generation.
Persistent quarterly cash consumption necessitates roughly 150 to 200 million shares of dilution, creating a divergence between enterprise and per-share returns.
Pharmaceutical alliances with Genentech and Sanofi act as essential sovereign buffers, delivering non-dilutive milestone capital that defers predatory financing.

Deep Dive

The outside market treats the stock as a speculative artificial intelligence showcase whose promise has deflated following early clinical trial failures and high short interest. Wall Street consensus fixates on an impending cash cliff and chronic quarterly revenue volatility, assuming heavy share dilution is unavoidable and heavily discounting multi-billion-dollar pharmaceutical milestone agreements as promotional narrative rather than durable financial backing.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd establishes no compelling directional gap at prevailing trading levels, as clinical optionality and structural financing dilution largely offset. The market's critical misread lies in treating the business as an empty software platform, overlooking over $500 million in realized non-dilutive partner inflows and a 40% reduction in operating cash burn. However, bulls overlook that lead asset REC-4881 was in-licensed, meaning computational screening alone has not eliminated human clinical attrition.

Repricing catalyst

A formal FDA agreement on registrational protocol and surrogate endpoints for REC-4881 in early 2027, paired with necessary balance-sheet recapitalization, serves as the decisive convergence catalyst. Clear regulatory guidelines will force market participants to reprice tangible orphan drug exclusivity against the precise share count issued to finance Phase 3 trials, triggering short covering and aligning market valuation with asset-level pharmacology.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of Federal Reserve benchmark interest rates near 4.0% and ten-year Treasury yields hovering near 5.0% acts as a persistent headwind. Elevated risk-free discount rates compress the discounted net present value of pre-commercial biotechnology cash flows projected beyond 2029, while tightening external capital markets makes equity refinancing exceptionally punitive.

Published consensus context

Advisor disagreement

The primary disagreement centers on the economic balance between enterprise pipeline maturation and per-share dilution. Bullish models argue that over 500 million dollars in non-dilutive partner inflows and orphan-drug pricing power will allow the company to reach commercialization without severe equity debasement, driving multi-fold re-rating. Bearish frameworks contend that trailing free cash burn of 354 million dollars mathematically guarantees massive share issuance before 2028, capping per-share gains regardless of scientific milestones. This tension will be resolved by the regulatory trial design agreed with the FDA for REC-4881 and the scale of subsequent capital raises.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Lead asset clinical registrational advancement: REC-4881 demonstrated a 43% median polyp burden reduction in Phase 2 trials for familial adenomatous polyposis. Advancing this rare-disease asset toward an FDA registrational pathway provides the company with its nearest commercial prospect in a disease lacking approved medical therapy, substantially expanding pipeline net present value. Expected impact: +32%.
Pharma partnership milestone cash monetization: Collaborations with Roche, Genentech, and Sanofi have delivered over $500 million in cumulative non-dilutive funding. Continued discovery option exercises and preclinical nominations inject high-margin milestone payments directly into the income statement, validating platform industrial utility while subsidizing clinical development expenses without immediate equity dilution. Expected impact: +26%.
Post-merger operating expense containment: Management curtailed 2026 cash operating expense guidance below $375 million following the Exscientia integration, reducing pro forma spending by nearly 40%. Pruning non-viable programs and extracting administrative synergies slows liquid treasury burn, extending the operational cash runway into early 2028 and deferring urgent equity refinancing rounds. Expected impact: +20%.
Industrialized automated phenomics discovery flywheel: Pairing high-throughput robotic wet laboratories with automated chemical design and supercomputing architecture compresses hit-to-lead timelines from years to quarters. By generating massive proprietary perturbational datasets, the platform reduces preclinical discovery unit costs and commands sustainable licensing interest across multi-target biopharmaceutical partnership frameworks. Expected impact: +15%.

Top frictions and headwinds

Structural cash burn dilution overhang: Annual free cash flow burn exceeding $300 million against trailing revenue under $60 million guarantees liquid depletion before self-funding is achieved. With cash reserves extending runway only into early 2028, management will inevitably issue substantial equity, expanding the share count and transferring pipeline appreciation to new capital providers. Expected impact: -32%.
Translational clinical trial attrition reality: Computational phenotypic screening cannot circumvent historical Phase 2 human clinical failure rates exceeding 70%, as demonstrated by previous candidate terminations. Inevitable trial attrition across internal and partnered oncology programs triggers periodic asset write-downs and impairs investor confidence in the predictive superiority of platform algorithms. Expected impact: -25%.
High interest rate valuation compression: Federal Reserve policy rates near 4.00% and ten-year Treasury yields approaching 5.0% impose severe hurdle rates on pre-commercial biotechnology. Elevated discount rates compress long-duration pipeline cash-flow multiples, while tight institutional credit conditions elevate the required cost of equity capital across public markets. Expected impact: -20%.
Lumpy collaboration revenue recognition volatility: Top-line performance relies heavily on partner-directed discovery milestones rather than predictable commercial product sales, causing quarterly revenues to fluctuate wildly. Milestone timing droughts produce severe headline revenue contraction, generating negative operating leverage against fixed laboratory overhead and leaving the equity vulnerable to periodic liquidity panics. Expected impact: -15%.

Tail risks

Pivotal trial efficacy failure in FAP: Should lead candidate REC-4881 fail to replicate polyp regression or demonstrate chronic off-target toxicities in expanded patient cohorts, the company's primary near-term value anchor would be eliminated. Losing the lead clinical program would severely damage faith in platform translatability, triggering an immediate equity collapse toward liquidation cash value. Probability: +36%. Expected impact: -55%.
Distressed dilutive equity down-round financing: If partnership milestone disbursements stall while clinical trial costs accelerate into 2028, management could face acute cash depletion amid hostile capital market conditions. Being forced into an emergency equity offering at a severe discount would heavily dilute existing common equity, permanently impairing per-share value and entrenching a depressed valuation trap. Probability: +32%. Expected impact: -45%.

Tail opportunities

Accelerated FDA approval for REC-4881: If the FDA grants Breakthrough Therapy designation and approves an accelerated registration pathway for REC-4881 based on surrogate polyp reduction, commercialization could occur by 2029 without a costly Phase 3 study. This would eliminate substantial trial expense and accelerate high-margin orphan revenue. The outcome remains below 50% probability given stringent regulatory surrogate criteria. Probability: +32%. Expected impact: +85%.
Strategic takeover by pharmaceutical partner: A major collaboration partner like Roche or Sanofi could launch a corporate acquisition to internalize the BioHive supercomputing infrastructure and automated wet-lab chemistry platform. A takeover bid would provide immediate liquidity at a premium, though it carries sub-50% probability because pharmaceutical incumbents generally prefer licensing individual drug assets over acquiring capital-intensive platform overhead. Probability: +20%. Expected impact: +75%.

What to monitor

Thesis watchpoints

-- Confirmation: REC-4881 maintains greater than 40% median polyp reduction without dose-limiting toxicities during November 2026 data presentations.

Key insights

Deterioration: Cash operating burn exceeds $100 million quarterly or collaborative revenue drops below $10 million across consecutive quarters through 2027.
Reassessment: Unrestricted cash reserves fall below twelve months of operating runway without committed non-dilutive financing by late 2027.

Company Financial Analysis

Recursion Pharmaceuticals Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Recursion's financial performance highlights the erratic reality of an early-stage drug developer that has not yet commercialized a medicine. For the twelve months ending June 30, 2026, revenue stood at $54.9 million against an operating deficit of $544 million. Because the company depends on sporadic milestone payments from partners rather than steady product sales, revenue plunged nearly 60% year-over-year in the second quarter of 2026 after earlier project phases wrapped up. However, reported losses are beginning to narrow as management enforces strict spending discipline. Operating expenses fell considerably in recent quarters, reflecting post-merger streamlining and lower data purchase costs. Even with these savings, cash generation remains negative, meaning incoming partner payments cushion spending rather than achieving self-sufficiency.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 74.7M	USD -644.8M	USD -378.3M
2024	USD 58.8M	USD -463.7M	USD -372.9M
2023	USD 43.9M	USD -328.1M	USD -300.3M
2022	USD 39.7M	USD -239.4M	USD -120.9M
2021	USD 10M	USD -178.1M	USD -198.4M

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	--	TTM	Loss-making	USD / USD
2024	--	TTM	Loss-making	USD / USD
2023	--	TTM	Loss-making	USD / USD
2022	--	Annual	Loss-making	USD / USD
2021	--	Annual	Loss-making	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability margins remain deeply negative, reflecting an R&D-heavy business where laboratory running costs vastly exceed early partnership payments. In fiscal 2025, gross margin registered at negative 62%, while operating margins remained below negative 300% due to ongoing laboratory overhead and clinical trial expenses. These severe deficits are a natural feature of pre-commercial biotechnology rather than a temporary slump. High-throughput automated screening carries significant fixed costs that cannot be scaled down easily when milestone payments pause. Lasting profit margins will only appear once internally owned drug candidates secure regulatory approval or yield substantial commercial sales royalties.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD -648.1M	-867.9%	-863.4%
2024	USD -479M	-814.1%	-788.0%
2023	USD -350.1M	-797.8%	-747.7%
2022	USD -245.7M	-619.3%	-603.4%
2021	USD -182.8M	-1827.8%	-1780.7%

Balance sheet and leverage

AI Review

On the surface, the balance sheet looks solid, holding approximately $557 million in cash and short-term investments with negligible funded debt. A conservative debt-to-equity ratio of 0.07 keeps the company safe from immediate bankruptcy or loan defaults, providing comfortable near-term liquidity. Nevertheless, this cash cushion is being consumed steadily. With annual cash burn running near $350 million, current reserves provide financial runway only into early 2028. Because there are no commercial product sales to replenish the treasury, the primary threat to existing investors is not debt default, but the need to sell new shares at low prices to keep operations running.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 78M	USD 743.3M	USD 665.3M net cash	5.50x
2024	USD 108.5M	USD 594.4M	USD 485.9M net cash	3.81x
2023	USD 50.7M	USD 391.6M	USD 340.9M net cash	4.70x
2022	USD 51M	USD 549.9M	USD 498.9M net cash	5.68x
2021	USD 11.5M	USD 516.6M	USD 273.6M net cash	11.46x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management has shifted its spending strategy from building massive physical infrastructure toward running targeted clinical trials. In earlier years, capital expenditures consumed a significant portion of revenue as the company constructed robotic wet laboratories and the BioHive supercomputing cluster. By 2025, physical capital spending dropped below 9% of revenue as these primary facilities reached completion. This reduction preserves cash, but it does not make drug development cheap. The true capital commitment now resides in research and clinical trial execution, which consumed $425 million in 2025. Rather than buying more supercomputers, the company is spending its treasury to test potential medicines in human patients.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 6.5M	USD 425.3M
2024	USD 13.7M	USD 314.4M
2023	USD 12M	USD 241.2M
2022	USD 37.4M	USD 155.7M
2021	USD 39.8M	USD 135.3M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	-5	+2.5%	Not available	ORIGINAL
5Y	NEUTRAL	14	+39.9%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	3.52	4.03	4.29	14
+6M	March 18, 2027	3.31	3.97	4.5	14
+9M	June 18, 2027	3.48	4.11	4.82	14
+1Y	September 18, 2027	3.13	3.93	5.11	14
+15M	December 18, 2027	2.91	3.82	4.95	14
+18M	March 18, 2028	2.68	3.68	5.05	14
+21M	June 18, 2028	2.66	3.82	5.3	14
+2Y	September 18, 2028	2.45	3.84	5.23	14
+27M	December 18, 2028	2.51	4.01	5.98	14
+30M	March 18, 2029	2.47	4.01	5.88	14
+33M	June 18, 2029	2.25	4.16	6.53	14
+3Y	September 18, 2029	2.31	4.2	6.79	14
+39M	December 18, 2029	2.15	4.36	7.26	14
+42M	March 18, 2030	2.07	4.37	7.55	14
+45M	June 18, 2030	2.22	4.65	8.4	14
+4Y	September 18, 2030	2.1	4.72	9.21	14
+51M	December 18, 2030	1.99	4.93	9.87	14
+54M	March 18, 2031	2.03	5.07	10.57	14
+57M	June 18, 2031	1.95	5.21	11.62	14
+5Y	September 18, 2031	1.89	5.36	12.2	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The synthesized consensus across all reports reveals a consistent economic pattern: clinical validation in lead candidate REC-4881 and disciplined operational expense containment toward 375 million dollars annually are actively competing against structural cash burn and unavoidable equity dilution before 2028. Reports that treat platform artificial intelligence as self-funding software are systematically downweighted, as empirical evidence demonstrates that biological drug development requires costly clinical trial execution. Conversely, reports emphasizing capital-structure arithmetic—specifically that enterprise pipeline growth will be diluted across an expanding share count—receive higher weight due to superior causal consistency. The strongest credible contrarian insight confirms that lead clinical asset REC-4881 was externally in-licensed rather than generated de novo by algorithms, proving that platform validation remains tied to conventional pharmacological translation rather than pure computational superiority. Weight allocations appropriately balance non-dilutive pharmaceutical milestone inflows against relentless equity dilution and macroeconomic discount-rate pressures.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight9.9/100

This report provides strong causal clarity regarding share-count expansion and the structural difference between enterprise progress and per-share returns. It grounds valuation in disciplined asset-level sums rather than platform multiples, correctly incorporating in-licensed asset mechanics while acknowledging lead clinical optionality.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight9.9/100

This submission offers exceptional granular accounting analysis, highlighting the pre-loaded at-the-market equity facility and distinguishing non-cash charges from recurring cash burn. Its realistic recognition that expense cuts buy time rather than deliver self-funded profitability makes its balanced path highly credible.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight7.9/100

The perspective balances legitimate Phase 2 polyp reduction in familial adenomatous polyposis against the mechanical depletion of liquid balances. Its emphasis on intermediate dilutive equity raises before registrational completion is economically consistent with operating cash burn and high macroeconomic discount rates.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight7.9/100

Demonstrating forensic rigor, this analysis correctly notes that the lead clinical asset originated externally, puncturing unverified claims of de novo computational discovery. Its valuation friction accurately models the compression of steep price-to-sales multiples under ongoing equity issuance and historical pipeline attrition.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight7.9/100

This report astutely identifies the company's evolution as an adaptive consolidator post-Exscientia. It reconciles operational expenditure limits with recurring partner milestone tranches, presenting a credible path of volatile range-bound trading anchored by gradual registrational progress.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight6.9/100

Providing a keen assessment of pharmaceutical sponsorship, this report captures how alliances buffer operational cash outflows. It tends toward optimistic multiple re-expansion but correctly highlights statutory orphan exclusivity and governance realignment under experienced drug-development leadership.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight6.9/100

A balanced evaluation emphasizing the multi-year lag between preclinical automated screening and human clinical proof. It accurately reflects the burden of trailing operating losses against volatile collaboration revenue, applying a reasonable discount to speculative biological foundation model claims.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight6.9/100

Focusing sharply on capital structure, this analysis traces the unavoidable collision between operating cash burn and the early-2028 runway boundary. Its rationale on dilution capping multiple expansion is sound, though it moderately underestimates the upside of accelerated regulatory surrogate endpoints.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight6.9/100

A solid, fact-based synthesis connecting disciplined post-merger spending with clinical-stage pivot execution. It presents a balanced view of pipeline net present value versus share-count expansion, maintaining plausible return checkpoints across the five-year horizon.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight5.9/100

While properly identifying operational discipline under executive transition, the report assumes an overly aggressive commercial re-rating without sufficient allowance for subsequent registrational trial execution hurdles. The weight reflects its valuable articulation of partner milestone optionality while downweighting unhedged commercial optimism.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight5.9/100

The report provides a disciplined examination of owner earnings and structural cash burn. However, it slightly overstates terminal impairment by underweighting non-dilutive partner milestone inflows that demonstrably prolong operational runway, justifying a measured baseline weight.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight5.9/100

This analysis captures the operational reality of capital allocation shifting toward clinical execution after heavy supercomputing investments. It properly penalizes long-duration cash flows under elevated interest rates, though its price path somewhat exaggerates multiple contraction given existing pharmaceutical validation.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight5.9/100

The framework effectively models the macroeconomic regime and discount-rate sensitivity for pre-revenue biotechnology. However, its long-term path discounts future milestone revenues somewhat excessively relative to historical partner cash realization, warranting a moderate weighting.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight5.0/100

The submission forcefully details the risks of negative operating leverage and physical consumable costs in automated biology. However, its path models near-unrelieved equity erosion, discounting legitimate orphan-market clinical proof points and partner commitment excessively.

Skip to references

Research Provenance

References & Context

This Recursion Pharmaceuticals consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 84 deduplicated sources retained for this batch.

01Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
02RECURSION PHARMACEUTICALS, INC. - Form 8-K - FY2026sec.gov
03recursionjpm2026presentasec.gov
04Recursion Pharmaceuticals (RXRX) Earnings Report Q2 2026 | Miss, EPS & Revenue | 24/7 Wall St.247wallst.com
05Recursion Eyes Breakthrough With REC-4881 Drug, But Shares Pull Back - Recursion Pharmaceuticals (NASDAQ: - Benzingabenzinga.com
06Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Recursion Pharmaceutic - Benzingabenzinga.com
07RXRX Forecast, Price Target & Analyst Ratings | ChartMill.comchartmill.com
08RXRX Stock Price | Analyst Target 6.43 & Hold Consensusetoro.com
09Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Pointsgenengnews.com
10Recursion Announces CEO Transition Plan to Drive Next Phase of Growthglobenewswire.com
11Recursion Q1 2026 slides: pipeline advances amid revenue shortfall By Investing.cominvesting.com
12MAY 6, 2026 - Recursion Pharmaceuticals, Inc.ir.recursion.com
13Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeksir.recursion.com
14Recursion Pharmaceuticals, Inc. - Press Releasesir.recursion.com
15Recursion Pharmaceuticals, Inc. - Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updateir.recursion.com

And 69 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

4 fields

capitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities

annual: 2019-12-31–2025-12-31, 7 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.